January 23rd 2024
Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
December 26th 2023
Innovative Approach to Precision Trial Design: NCI-MATCH and Beat AML
January 25th 2017At the 58th annual meeting of the 58th American Society of Hematology, representatives from 2 national clinical trials, Beat AML and NCI-MATCH, detailed how they were incorporating genomic profiling to assign patients to different treatment arms.
Read More
Healthcare Utilization and Costs Associated With the Treatment of Relapsed/Refractory MM
January 25th 2017A poster presented at the 58th Annual Meeting & Exposition of the American Society of Hematology compared the utilization patterns and associated costs for recently approved and older drugs in patients with relapsed/refractory multiple myeloma in the United States.
Read More
Rare Disease Information Websites Vary in Quality, Study Finds
January 18th 2017Patients with rare diseases often turn to the Internet for information on their illness, but an analysis of some of these websites found that their content often failed to meet important quality criteria and neglected key information categories.
Read More
RESONATE-2 Continues to Impress With Single-Agent Ibrutinib for CLL/SLL at 29 Months
January 18th 2017Despite the complexities associated with treating older patients diagnosed with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), patients in the RESONATE-2 trial continue to present a favorable response to single-agent ibrutinib at a follow-up of 29 months.
Read More
Nearly Half of New Drugs Approved in 2016 Were Orphan Drugs
January 17th 2017Among the 9 new orphan drugs approved by the FDA in 2016 were 3 treatments for rare diseases that, so far, had no approved treatments: Duchenne muscular dystrophy, spinal muscular atrophy, and severe hepatic veno-occlusive disease.
Read More
Cytokine Biomarkers Can Predict Response to CAR T-Cell Treatment in CLL
January 16th 2017At the 58th American Society of Hematology Annual Meeting & Exposition, Jan Joseph Melenhorst, PhD, presented results of a study evaluating biomarkers of response to anti-CD19 CAR T-cell treatment in patients diagnosed with chronic lymphocytic leukemia (CLL).
Read More
First Patient Treated With Jakafi in Phase 2 Graft-Versus-Host Disease Study
January 3rd 2017The first patient has been treated with ruxolitinib (Jakafi), by Incyte Corporation, for steroid-refractory acute graft-versus-host disease, as part of the REACH-1 phase 2 trial. The trial is evaluating ruxolitinib in combination with corticosteroids.
Read More
The High Cost of Home Care for Children With Special Healthcare Needs
January 1st 2017Caring at home for children with special healthcare needs brings high costs to families. A study by researchers at the University of Southern California, Boston Children’s Hospital, and RAND Corp., placed the uncompensated medical cost at nearly $36 billion annually.
Read More
Reducing Radiation Dose in Oropharynx Cancer Can Improve QOL
December 28th 2016A new clinical study to reduce the unwanted side effects of radiation in patients with human papillomavirus (HPV)—positive oropharynx cancers has found that reducing the dose of radiation can maintain the cure rates but avoid some of the late treatment-associated toxicities.
Read More
Innovative Approach to Precision Trial Design: NCI-MATCH and Beat AML
December 5th 2016Representatives from the Beat acute myeloid leukemia (AML) and National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH), which incorporate genomic profiling to assign patients to different treatment arms, provided an insight on trial design and a progress report.
Read More
RESONATE-2 Continues to Impress With Single-Agent Ibrutinib for CLL/SLL at 29 Months
December 5th 2016Older patients diagnosed with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) continue to present a favorable response to single-agent ibrutinib, at a follow-up of 29 months, in phase 3 of the RESONATE-2 trial.
Read More
Early Results Show Palbociclib Helps Sustain Patient Response to Ibrutinib in MCL
December 3rd 2016Early phase 1 results show that including the cyclin-dependent kinase 4/6 inhibitor palbociclib in the treatment of patients with mantle cell lymphoma (MCL) can help overcome resistance to ibrutinib.
Read More
Dr David Porter Compares Use of CAR T-Cells for B-Cell and Solid Tumors
December 3rd 2016Chimeric antigen receptor (CAR) T-cells have been dramatically effective in treating B-cell cancers, according to David L. Porter, MD, of the University of Pennsylvania Health System. He also identified the use of CAR T-cells for treating solid tumors as a research area that will see more development in the coming years.
Watch
Precision CAR-T Trial Shows Early Signs of Success in Multiple Myeloma
December 1st 2016Interim data analysis of a phase 1 trial of chimeric antigen receptor-T cells (CAR-T) targeting the B-cell maturation antigen in heavily pretreated patients with multiple myeloma has identified an objective anti-tumor response, with limited toxicity.
Read More
ICU Admission Reduces Survival, Augments Costs Among Patients With AML
November 17th 2016A study published by researchers from the Fred Hutchinson Cancer Research Center in Seattle has found that admission to the intensive care unit reduced survival and increased the cost of care among patients undergoing treatment for acute myeloid leukemia.
Read More